Amino Acid Metabolism, Glucose Metabolism
Conditions
Keywords
amino acid, glucose, metabolism, microdialysis, nutrition, stable isotope, macronutrient, biomarker
Brief summary
The goal of this clinical trial is to establish the relationship between macronutrient food intake and the resulting blood and intersticial fluid (ISF )levels of small molecule markers, as well as, validate wearable optical readers and data fusion algorithms to accurately predict individual-specific macronutrient availability in real time. The study involves 1 screening visit of approximately 2 hours and up to 4 study days of approximately 14 hours. Subjects will be asked to arrive in the fasted state on all study days. Fasting prior to screening is not required. On the screening visit, body weight, height, and body composition by Dual-energy X-ray absorptiometry (DXA) will be measured. In addition, habitual dietary intake, physical activity level (PASE), and quality of life (SGRQ-C) will be assessed.
Detailed description
On each study day, body weight and height will be measured. An in-dwelling catheter will be inserted in a peripheral vein of the lower arm or hand to enable blood sampling. The arm will be put in a hot box to allow collecting arterialized venous blood samples. After taking a baseline blood sample, the predefined meal will be consumed within 10 min. Small arterialized venous blood samples (5 ml) will subsequently be drawn multiple times. Samples will be collected in predefined tubes, plasma/serum separated, aliquoted, and stored at -80 deg. Celsius for later assays and/or send to a local accredited laboratory for the concentrations of amino acids and other parameters (including amino acids, fatty acids, glucose, insulin). In the opposite limb, a commercially available microdialysis catheter will be placed in the forearm following standard operating procedures developed by the European Academy of Allergy & Clinical Immunology Task Force on Skin Microdialysis. Dialysate will be collected in 30-minute aliquots in microvials for the duration of the study day. Microvials will be weighed before and after sample collection. A syringe filled with perfusate containing mixture of stable tracer-labelled amino acids and glucose will be infused through the syringe pump at a controlled rate. On each of the study days, subjects will consume two meals with defined composition of macronutrients eight hours apart.
Interventions
OTHERMeal set A
morning meal: low carbohydrate, low protein, low fat afternoon meal: high carbohydrate, high protein, high fat
OTHERMeal set B
morning meal: low carbohydrate, high protien, low fat meal afternoon meal: high carbohydrate, low protein, high fat meal
OTHERMeal set C
morning meal: low carbohydrate, low protien, low fat meal afternoon meal: high carbohydrate, high protein, low fat meal
OTHERMeal set D
morning meal: high carbohydrate, low protien, low fat meal afternoon meal: low carbohydrate, high protein, high fat meal
Sponsors
Texas A&M University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
SINGLE (Outcomes Assessor)
Masking description
Laboratory staff and data scientists will not know the meals received when analyzing samples and initial statistical modeling
Eligibility
Sex/Gender
ALL
Age
50 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* Ability to walk, sit down and stand up independently * Age 50-75 years old * Ability to lie in supine or slightly elevated position for approximately 13 hours * BMI between 25 and 35 * Willingness and ability to comply with the protocol
Exclusion criteria
* Established diagnosis of malignancy * Established diagnosis of Insulin or non-Insulin Dependent Diabetes Mellitus * History of untreated metabolic diseases including hepatic or renal disorder * Currently on anticoagulants (i.e., warfarin, factor X inhibitors or direct thrombin inhibitors) * History of deep vein thrombosis, pulmonary embolisms, or known clotting disorders * Presence of acute illness or metabolically unstable chronic illness * Recent myocardial infarction (less than 1 year) * Known allergy or intolerance to any of the meal components * Any other condition according to the PI or nurse that was found during the screening visit, that would interfere with the study or safety of the patient * Failure to give informed consent or Investigator\'s uncertainty about the willingness or ability of the participant to comply with the protocol requirements
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Glucose metabolism | Up to 14 hours per study visit, up to 4 visits | Prediction models of postprandial plasma glucose in relation to the macronutrient content of predefined meals as assessed by plasma and/or ISF concentrations of amino acids, glucose, and/or triglycerides |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Amino acid metabolism | Up to 14 hours per study visit, up to 4 visits | Prediction models of postprandial plasma amino acid patterns in relation to the macronutrient content of predefined meals as assessed by plasma and/or ISF concentrations of amino acids and/or glucose |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORNicolaas Deutz, MD, PhD
Texas A&M University
PRINCIPAL_INVESTIGATORMichael McShane, PhD
Texas A&M University
Outcome results
None listed